Azafaros
Vanessa King is a Venture Partner at Abingworth, LLP. Prior to this, she was Chief Executive Officer of Cadent Therapeutics, where she led its transformation into a precision medicine neuroscience company with a clinical pipeline. Before that, Vanessa was Vice President Business Development at deCODE Genetics, yielding its acquisition by Amgen in 2012 for USD 415 million.
She has also served as Executive Chairman of Tiaki Therapeutics, been an Entrepreneur in Residence at Atlas Venture, and held senior business development and operating positions at Amgen and Novartis.
Vanessa received a PhD in Molecular Genetics from the University of Cambridge.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Azafaros
Azafaros is developing new treatment options to help patients with rare metabolic disorders. Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential.